Terumo to Buy OrganOx for $1.5B to Enter Transplant Field

Terumo to buy OrganOx for $1.5B to enter transplant field

OrganOx has the potential to capture a greater share of the liver transplant market, where it competes with TransMedics Group, Needham analyst Mike Matson wrote.

Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history - Tech Startups

OrganOx, the Oxford University spinout that has been quietly reshaping the field of organ transplantation, is being acquired by Tokyo-based Terumo Corporation in a $1.5 billion deal — the largest acquisition of a university spinout in the UK to date. […] The post Oxford spinout OrganOx acquired by Terumo for $1.5 billion, largest university spinout exit in UK history first appeared on Tech Startups.

Terumo buys OrganOx in $1.5B deal

Terumo Corporation (TRUMF) has entered into a definitive agreement to acquire OrganOx Limited, a company specializing in advanced organ preservation devices, for approximately $1.5 billion. The deal will make OrganOx a wholly owned subsidiary of

Terumo to Buy UK Organ Tech Provider OrganOx for $1.5 Billion

Terumo Corp. has agreed to buy UK-based organ medical tech company OrganOx Ltd. in a deal valued at around $1.5 billion, seeking entry into the organ transplant field.

Oxford spin-out OrganOx sold to Japan’s Terumo in $1.5bn deal

Oxford University spin-out OrganOx, the pioneering transplant technology company, has been sold to Japanese medical devices group Terumo in a $1.5 billion (£1.2 billion) deal. The acquisition, one of the largest ever for a UK medical technology business, underscores Britain’s strength in scientific innovation but will also intensify debate about the country’s ability to retain ownership of its most successful spin-outs. OrganOx was founded in 20…

MedTech OrganOx sold in £1.1bn deal

Oxford-based OrganOx has been sold in a mammoth £1.1bn deal. The company’s pioneering liver perfusion technology has transformed outcomes for transplant patients worldwide. One of UK’s largest MedTech exits to date, it marks investor BGF’s largest ever return, generating £175m of proceeds – a 10x multiple exit on its initial investment. BGF first invested in OrganOx in 2019 and has provided seven rounds of investment, including a £20m commitment…